Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068471 · ClinicalTrials.gov registry record · Phase 1
Anidulafungin in Treating Immunocompromised Children With Neutropenia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00068471: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00068471 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00068471, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Anidulafungin may be effective in preventing fungal infections in immunocompromised children who have neutropenia. PURPOSE: This phase I/II trial is studying the side effects of anidulafungin and to see how well it works in preventing fungal infections in immunocompromised children with neutropenia caused by chemotherapy or aplastic anemia.
Interventions
- DRUG anidulafungin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-07 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068471
The ClinicalTrials.gov registry entry for NCT00068471 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which anidulafungin is the first listed.
NCT00068471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00068471 about?
NCT00068471 is a clinical study titled "Anidulafungin in Treating Immunocompromised Children With Neutropenia". RATIONALE: Anidulafungin may be effective in preventing fungal infections in immunocompromised children who have neutropenia. PURPOSE: This phase I/II trial is studying the side effects of anidulafungin and to see how well it works in preventing fungal infections in immunocompromised children with ...
What is the current status of trial NCT00068471?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-07. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00068471?
The interventions under investigation include: anidulafungin (DRUG).
Who is sponsoring clinical trial NCT00068471?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.